Table 3.
Summary of complete study cohort (33 subjects) demographic and clinical characteristics with respect to each group (Early PD patients and Controls).
| Early PD patients | Controls | Statistical Significance | |
|---|---|---|---|
| n (total n = 33) | 18 | 15 | N.A. |
| Demographics | |||
| Women # (%) | 4 (22%) | 7 (46%) | n.s. (p = 0.24) |
| Men # (%) | 14 (78%) | 8 (54%) | n.s. (p = 0.24) |
| Avg. Age, years (std) | 61 (8.4) | 57 (3.9) | n.s. (p = 0.67) |
| Subjects #/# who completed Education Level H/U | 4/14 | 1/14 | n.s. (p = 0.31) |
| Avg. Years of Smartphone Usage (std) | 3.4 (1.6) | 2.8 (2.6) | n.s. (p = 0.15) |
| Clinical characteristics | |||
| Avg. Disease onset, years (std) | 2.5 (1.6) | N.A. | N.A. |
| Avg. UPDRS Part III score (std) | 16.9 (7.8) | 0.0 (0.0) | sig. (p < 0.001) |
| PD patients #/# under treatment/De-novo | 14/4 | N.A. | N.A. |
| PD patients #/# with right/left most affected side | 13/5 | N.A. | N.A. |
| Subjects #/#/# with dominant hand Right/Left/Ambidextrous | 18/0/0 | 15/0/0 | N.A. |
| Avg. LEDDa, mg (std) | 247 (110) | N.A. | N.A. |
With the exception of clinical characteristics (UPDRS Part III score), the two groups are reasonably matched in terms of demographics as no significant differences (p < 0.05) are observed (two-sided Mann-Whitney U test). aAvg. Levodopa Equivalent Daily Dose (LEDD) concerns only PD patients under treatment (n = 14). N.A.: not applicable; sig.: significant; n.s.: non-significant.